Skip to main content
. 2021 Feb 15;12:636375. doi: 10.3389/fimmu.2021.636375

Figure 1.

Figure 1

Illustrating re-activation of effector T-cells to viral antigens after combined IMiD and checkpoint therapy. (Created with BioRender.com).